HUP0301781A2 - Proteáz inhibitor hatású 4-amino-3-oxo-azepám-származékok és alkalmazásuk - Google Patents

Proteáz inhibitor hatású 4-amino-3-oxo-azepám-származékok és alkalmazásuk

Info

Publication number
HUP0301781A2
HUP0301781A2 HU0301781A HUP0301781A HUP0301781A2 HU P0301781 A2 HUP0301781 A2 HU P0301781A2 HU 0301781 A HU0301781 A HU 0301781A HU P0301781 A HUP0301781 A HU P0301781A HU P0301781 A2 HUP0301781 A2 HU P0301781A2
Authority
HU
Hungary
Prior art keywords
alkyl
carbon atom
protease inhibitors
azepan
ones
Prior art date
Application number
HU0301781A
Other languages
English (en)
Inventor
Maxwell D. Cummings
Robert W. Marquis
Yu Ru
Scott K. Thompson
Daniel F. Veber
Dennis S. Yamashita
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of HUP0301781A2 publication Critical patent/HUP0301781A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)

Abstract

A találmány (I) általános képletű proteáz inhibitorok különösenkatepszin S inhibitoroknak - amelyek képletében R1 jelentése (a); (b)vagy (c) általános képletű csoport; R2 hidrogénatom, alkil-,cikloalkil-(0-6 szénatomos alkil)-, Ar-(0-6 szénatomos alkil)-, Het-(0-6 szénatomos alkil)-, R9C(O)-, R9C(S)-, R9SO2-, R9OC(O)-,R9R11NC(O)-, R9R11NC(S)-, R9(R11)NSO2-, csoport; R< hidrogénatom, alkil-, Ar-(0-6 szénatomos alkil)- ésHet-(0-6 szénatomos alkil)-csoport; és R<' hidrogénatom, alkil-,cikloalkil-(0-6 szénatomos alkil)-, Ar-(0-6 szénatomos alkil)- és Het-(0-6 szénatomos alkil)-csoport - vagy megelőzésében történőfelhasználására, továbbá az említett felhasználásban alkalmazásrakerülő új vegyületekre vonatkozik. Ó
HU0301781A 2000-04-18 2001-04-17 Proteáz inhibitor hatású 4-amino-3-oxo-azepám-származékok és alkalmazásuk HUP0301781A2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19849300P 2000-04-18 2000-04-18
US27381101P 2001-03-07 2001-03-07
PCT/US2001/012326 WO2001089451A2 (en) 2000-04-18 2001-04-17 Protease inhibitors

Publications (1)

Publication Number Publication Date
HUP0301781A2 true HUP0301781A2 (hu) 2003-09-29

Family

ID=26893840

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301781A HUP0301781A2 (hu) 2000-04-18 2001-04-17 Proteáz inhibitor hatású 4-amino-3-oxo-azepám-származékok és alkalmazásuk

Country Status (17)

Country Link
EP (1) EP1278502A4 (hu)
JP (1) JP2004526662A (hu)
KR (1) KR20020089482A (hu)
CN (1) CN1431904A (hu)
AR (1) AR032319A1 (hu)
AU (1) AU9050701A (hu)
BR (1) BR0108954A (hu)
CA (1) CA2406829A1 (hu)
CO (1) CO5280088A1 (hu)
CZ (1) CZ20023460A3 (hu)
HK (1) HK1053785A1 (hu)
HU (1) HUP0301781A2 (hu)
IL (1) IL151087A0 (hu)
MX (1) MXPA02010276A (hu)
NO (1) NO20025005L (hu)
PL (1) PL366040A1 (hu)
WO (1) WO2001089451A2 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092563A2 (en) * 2001-05-17 2002-11-21 Smithkline Beecham Corporation Protease inhibitors
US20050030912A1 (en) * 2002-08-22 2005-02-10 Enikia L.L.C. Use of hybrid (HW/DSP/MCU/SW) architectures for powerline OFDM communication field
RU2478378C2 (ru) 2002-09-24 2013-04-10 Новартис Аг Органические соединения
AU2003273697A1 (en) * 2002-10-08 2004-05-04 Merck Frosst Canada Ltd 4-amino-azepan-3-one compounds as cathepsin k inhibitors useful in the treatment of osteoporosis
US7297714B2 (en) * 2003-10-21 2007-11-20 Irm Llc Inhibitors of cathepsin S
US20100292298A1 (en) * 2006-02-21 2010-11-18 Agency For Science, Technology And Research Method and reagents for treating hepatic fibrosis and inflammation
EP2216047A4 (en) * 2007-10-24 2011-12-28 Nat Univ Corp Tokyo Med & Dent REGULATOR FOR SIGNALING THE TOLL LIKE RECEPTOR WITH A CATHEPSIN INHIBITOR AS AN ACTIVE SUBSTANCE
EP2303250A1 (en) 2008-06-20 2011-04-06 Novartis AG Paediatric compositions for treating1 multiple sclerosis
LV15485B (lv) * 2018-09-13 2020-06-20 Latvijas Organiskās Sintēzes Institūts Selenofēnhromenonu hidroksāmskābes, to izgatavošana un izmantošana angioģenēzes inhibīcijā

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518528A (en) * 1983-05-19 1985-05-21 Rasnick David W α Amino fluoro ketones
TW494094B (en) * 1993-04-29 2002-07-11 Vertex Pharma Peptide analogs as irreversible interleukin-1β protease inhibitors and pharmaceutical compositions comprising the same
DZ2285A1 (fr) * 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
CN1253441C (zh) * 1998-12-23 2006-04-26 史密丝克莱恩比彻姆公司 蛋白酶抑制剂
CN1416346A (zh) * 2000-03-21 2003-05-07 史密丝克莱恩比彻姆公司 蛋白酶抑制剂
WO2002017924A1 (en) * 2000-09-01 2002-03-07 Smithkline Beecham Corporation Method of treatment

Also Published As

Publication number Publication date
CA2406829A1 (en) 2001-11-29
JP2004526662A (ja) 2004-09-02
KR20020089482A (ko) 2002-11-29
MXPA02010276A (es) 2003-04-25
EP1278502A2 (en) 2003-01-29
BR0108954A (pt) 2006-05-09
AR032319A1 (es) 2003-11-05
HK1053785A1 (zh) 2003-11-07
AU9050701A (en) 2001-12-03
NO20025005L (no) 2002-12-06
EP1278502A4 (en) 2003-05-21
PL366040A1 (en) 2005-01-24
NO20025005D0 (no) 2002-10-17
CO5280088A1 (es) 2003-05-30
IL151087A0 (en) 2003-04-10
WO2001089451A3 (en) 2002-04-04
WO2001089451A2 (en) 2001-11-29
CN1431904A (zh) 2003-07-23
CZ20023460A3 (en) 2004-03-17

Similar Documents

Publication Publication Date Title
MXPA02012033A (es) Derivados de 2-aminocarbonil-9h-purina.
NL350075I2 (hu)
MX2007005408A (es) Compuestos de aminoquinazolinas.
TNSN07235A1 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
AU2002319814A1 (en) Substituted 1h-dihydropyrazoles, their preparation and use
IL164490A (en) Phosphonate analogs of hiv protease inhibitor compounds
AP2001002204A0 (en) Pyrazole derivatives.
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
GEP20115211B (en) Terphenyl derivatives for treatment of alzheimer&#39; s disease
MXPA02011370A (es) Iminoazinas substituidas.
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
RS41604A (en) Herbicidal agents containing benzoylpyrazoles and safeneres
IL158324A0 (en) Arylsulphonamides as anttiviral agents
HUP0301781A2 (hu) Proteáz inhibitor hatású 4-amino-3-oxo-azepám-származékok és alkalmazásuk
MXPA04002282A (es) Nuevos compuestos y preparaciones como inhibidores de la catepsina.
RS94603A (en) Novel compounds and compositions as cathepsin inhibitors
DK1644389T3 (da) Pyrinidinforbindelser med phosphonatgrupper som antivirale nukleotidanaloger
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
IL161843A0 (en) Use of 2-amino-4-pyridylmethyl-thiazoline dervatives as inhibitors of inducible no-synthase
HRP20090187T1 (en) Bengamide derivatives and use thereof for the treatment of cancer
DE60201074D1 (en) Pyrazolopyridinderivate
MXPA02007973A (es) Compuestos de aminoacidos y su uso como inhibidores de nep, ace y ece.
WO2007004090A3 (en) Improved processes for the preparation of purified solanesol, solanesyl bromide and solanesyl acetone
RS4904A (en) Pharmaceutical composition for the treatment of the decline and/or damage of cognitive functions
ATE427934T1 (de) Nicht-peptidische brs-3-agonisten

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees